Molecular Profiling of the Hippocampus of Children with Autism Spectrum Disorder

Lindsay Rexrode [a], Joshua Hartley [a], Kurt C. Showmaker [b], Michael W. Vandewege [b], Brigitte E. Martin [c], Estelle Blair [a], Ratna Bollavarapu[a], Rhenius B. Antonyraj[a], Keauna Hilton[a], Alex Gardiner[a], Jake Valeri[a,d], Barbara Gisabella[a,d], Michael Garrett [c], Theoharis C. Theoharides[e, f] and Harry Pantazopoulos[a,d]

[a]Department of Psychiatry and Human Behavior, University of Mississippi Medical School, Jackson, MS, USA

[b]Dasomics LLC, Madison MS, USA

[c]Department of Pharmacology and Toxicology, University of Mississippi Medical School, Jackson, MS, USA

[d]Program in Neuroscience, University of Mississippi Medical School, Jackson, MS, USA

[e]Institute of Neuro-Immune Medicine, Nova Southeastern University, Clearwater, FL, USA

[f]Department of Immunology, Tufts University School of Medicine, Boston, MA, USA

Correspondence to:

Harry Pantazopoulos, PhD

Department of Psychiatry and Human Behavior

University of Mississippi Medical School

2500 North State St

Jackson, MS 39232, USA

Phone: (601) 815-7983

E-mail: cpantazopoulos@umc.edu

Short title: Molecular Profiling of the Hippocampus in ASD

Key words: Autism spectrum disorders, development, hippocampus, synaptic signaling, immune response, extracellular matrix

Rexrode et al.

Abstract: Several lines of evidence point to a key role of the hippocampus in Autism Spectrum Disorders (ASD). Altered hippocampal volume and deficits in memory for person and emotion related stimuli have been reported, along with enhanced ability for declarative memories. Mouse models have demonstrated a critical role of the hippocampus in social memory dysfunction, associated with ASD, together with decreased synaptic plasticity. Chondroitin sulphate proteoglycans (CSPGs), a family of extracellular matrix molecules, represent a potential key link between neurodevelopment, synaptic plasticity, and immune system signaling. There is a lack of information regarding the molecular pathology of the hippocampus in ASD. We conducted RNAseq profiling on postmortem human brain samples containing the hippocampus from male children with ASD (n=7) and normal male children (3-14 yrs old), (n=6) from the NIH NeuroBioBank. Gene expression profiling analysis implicated molecular pathways involved in extracellular matrix organization, neurodevelopment, synaptic regulation, and immune system signaling. qRT-PCR and Western blotting were used to confirm several of the top markers identified. The CSPG protein BCAN was examined with multiplex immunofluorescence to analyze cell-type specific expression of BCAN and astrocyte morphology. We observed decreased expression of synaptic proteins PSD95 ($p<0.02$) and SYN1 ($p<0.02$), increased expression of the extracellular matrix (ECM) protease MMP9 ($p<0.03$), and decreased expression of MEF2C ($p<0.03$). We also observed increased BCAN expression with astrocytes in children with ASD, together with altered astrocyte morphology. Our results point to alterations in immune system signaling, glia cell differentiation, and synaptic signaling in the hippocampus of children with ASD, together with alterations in extracellular matrix molecules. Furthermore, our results demonstrate altered expression of genes implicated in genetic studies of ASD including SYN1 and MEF2C.

Introduction

Autism Spectrum Disorder (ASD) is a developmental condition impacting the global population with increasing prevalence [1], reported to be 1 in 45 in the United States [2]. ASD is characterized by impaired social interactions and communication along with stereotypic movements [3, 4]. The pathogenesis of ASD however is still unknown, limiting development of therapeutic and preventative strategies. Several lines of evidence point to a key role of the hippocampus in ASD. Altered hippocampal volume and deficits in memory for person and emotion related stimuli have been reported, along with enhanced ability for declarative memories [5-7]. Specifically, increased hippocampal volume was reported in children and adults with ASD [8]. Preclinical models have demonstrated a critical role of the hippocampus in social memory dysfunction associated with ASD, together with decreased synaptic plasticity [9, 10]. Abnormalities in neurodevelopmental and inflammatory processes are key features of ASD [11, 12] and may contribute to hippocampal dysfunction. Growing evidence indicates that altered immune system signaling during development is critically involved in ASD [13-18]. Brain imaging and human postmortem studies suggest that neuroinflammation is present in several brain regions in ASD [14, 15, 18]. Furthermore, a recent single cell RNAseq profiling study of postmortem brain samples implicates several microglial specific molecules [19] in ASD. Maternal immune activation results in sex-specific microglial alterations primarily impacting male offspring [16, 17, 20], reflective of the male prevalence of ASD [21].

Chondroitin sulphate proteoglycans (CSPGs) and their endogenous proteases are critically involved in mediating inflammation and represent key factors at the intersection of inflammation, neurodevelopment, and synaptic regulation. Chondroitin sulphate is a potent inhibitor of inflammation (for review see [22-24]. Several lines of evidence indicate that altered neurodevelopment plays a key role in ASD [12, 25, 26]. For example, neuronal and dendritic spine development is altered in the amygdala of children with ASD [11, 12]. Abnormalities in neuronal migration have also been reported [25, 26]. CSPGs are extracellular matrix molecules critically in involved in neuronal migration, glial cell maturation, and synaptic stabilization [27-29]. Work from our group and others have reported alterations in extracellular matrix (ECM) molecules including CSPGs in subjects with schizophrenia [30, 31]. Genetic factors and gene expression signaling

pathways implicated in ASD share a degree of overlap with Schizophrenia [32, 33]. Recent evidence suggests that these disorders may also share alterations in ECM molecules. Genome-wide association studies (GWAS) implicate several ECM genes in ASD, including genes encoding for endogenous proteases such as ADAMTS3, ADAMTS5, ADAMTS14 [34-38]. Increased levels of the CSPG protease matrix metalloproteinase 9 (MMP9) have been reported in amniotic fluid samples of children with ASD [39].

Despite the critical role of CSPGs in neurodevelopment, inflammation and synaptic regulation [23, 40-42], and evidence for their involvement in several psychiatric disorders [30, 43-45], the role of CSPGs in the brain of children with ASD has not been examined. We propose that CSPGs are shared downstream targets from several genetic and environmental factors that are at the intersection of neurodevelopment, inflammation, and synaptic regulation. As a first step in identifying the molecular pathology of the hippocampus in ASD, we conducted RNAseq profiling of human postmortem hippocampus samples from male children with ASD and age matched normotypic control subjects (3-14 yrs old) (Table 1). We focused on a neurodevelopmental time-window encompassing stages of synaptic development and refinement.

Methods

Human Subjects. Postmortem human brain tissues of ASD (n=7) and non-ASD (n=6) male children (3-14 yrs old) were obtained from the NIH NeuroBioBank at the University of Maryland, Baltimore MD. Tissue blocks containing the Hippocampus were used for these studies (Table 1). Available samples for RNA analysis consisted of ASD (n=7) and non-ASD (n=6). For Western Blotting studies, hippocampal protein samples were available from the same subjects along with three additional samples, resulting in ASD (n=8) and non-ASD (n=8) male children (Table 1). Characteristics of the subjects are listed in Table 1. Microscopy studies were conducted on a subset of frozen tissue sections from the same subjects consisting of 6 subjects with ASD and 6 control subjects in order to obtain cell type specific data and glial cell morphology information. Sections from the remaining subjects in the cohort did not display suitable cytoarchitecture for microscopy. Frozen blocks were sectioned at 30 μm thickness using a Leica CM 3050 S cryostat (Leica Biosystems, Buffalo Grove, IL). For fluorescent microscopy studies, sections were stained

with DAPI to identify hippocampal subregions and to confirm cell specific labeling. This study is limited to males only because ASD is four times more common in males than females, and to avoid any additional sex and hormonal variabilities.

RNAseq Profiling: RNA isolation, library preparation, and next generation sequencing was performed by the Molecular and Genomics Core Facility at the University of Mississippi Medical Center, as described previously [46]. Total RNA was isolated from tissue samples using the Invitrogen PureLink RNA Mini kit with Trizol (Life Technologies; Carlsbad, CA, USA) following manufacturer protocol. Quality control of total RNA was assessed using the Qiagen QIAxcel Advanced System for quality and Qubit Fluorometer for concentration measures. The RQI was 6.6 ± 2.1 (mean $\pm$ SD). Libraries were prepared using the TruSeq Stranded Total RNA LT Sample Prep Kit from Illumina (San Diego, CA, USA) per manufacturer's protocol using up to 1 ug of RNA per sample. Libraries were index-tagged, pooled for multiplexing (all 13 samples) and sequencing was performed on the Illumina NextSeq 500 platform using a paired-end read (2 x75 bp) protocol with the Illumina 150 cycle High-Output reagent kit.

RNAseq Bioinformatics Analysis: Differential expression of genes (i.e. mRNA and non-coding RNA) was assessed between subjects with ASD and controls. Reads were aligned to the NCBI GRCh38Decoy Refseq genome with the basespace application RNA-Seq Alignment (Version: 2.0.1 [workflow version 3.19.1.12+master]) that conducted both splice aware genome alignment with STAR alignment (version 2.6.1a, [47]) and transcriptome quantification with Salmon (version 0.11.2, [48]). Differential expression (DE) of the genes (DGE) were conducted with the DESeq2 (1.20.0, [49]) and tximport (version 1.8.0 , Soneson 2015) R packages using the BaseSpace RNA-Seq Differential Expression (version 1.0.1 [Illumina Secondary Analysis Software version 3.18.18.9+master]) application. Gene Set Enrichment Analysis (GSEA) was conducted with the ClusterProfiler R package [50] using the functions gseGO, gseKEGG, and gsePathway [51] for GO Biological Processes (BP) , KEGG , and Reactome geneset collections, respectively, each with the parameters pAdjustMethod = "BH", pvalueCutoff = 0.05, minGSSize = 20, and maxGSSize

Rexrode et al.

= 500. Plots were generated with R packages ggplot2 (Wickham 2016) and pheatmap (Kolde 2012). Heatmap visualizations were generated using ClustVis (https://biit.cs.ut.ee/clustvis/) and VolcaNoseR (https://huygens.science.uva.nl/VolcaNoseR) based on 'regularized log' transformation DESeq2 results. Raw sequencing reads were deposited into NCBI dbGaP (accession number pending).

qRT-PCR: Total RNA (0.5 µg) was used as a template for synthesis of cDNA in a total reaction volume of 20 µl using Invitrogen iScript™ Advanced cDNA synthesis kits (cat# 1725038, Invitrogen, Grand Island, NY). Twenty-eight transcripts identified as differentially expressed in RNAseq studies were chosen for validation as well as the downstream protease MMP9 and the inflammatory molecule IL1B. B2M and ACTB were used as reference genes. Pre-validated qPCR probes from Bio-Rad PrimerPC were used (see Supplementary table 2). qPCR was performed using 384 well plates with the Bio-Rad CFX 384 real-time PCR detection system and iQ-SYBR Green Supermix (cat# 1708880, Bio-Rad, Hercules, CA). PCR reactions contained 10µl of the SYBR Green PCR mix, 0.04µl of 100µM forward and reverse primers, 1µl of cDNA, in a final volume of 20µl using nuclease free water. For all primer pairs, PCR cycling conditions were 50°C for 2 min and 95°C for 2 min, followed by 50 cycles of 95°C for 15 sec, 60°C for 15 sec and 72°C for 1 min. PCR product quantification was performed by the relative quantification method [52, 53] and expressed as standardized arbitrary units [52].

Western blot analysis: Protein levels of MMP9, IL1β, PSD-95, SYN1, MEF2C, and DGCR6 were determined by Western blotting analysis. Initially, brain tissues were homogenized using lysis radio-immuno precipitation (RIPA) buffer in the presence of a protease inhibitor cocktails (Sigma- Aldrich, St. Louis, MO), followed by sonication using a Polytron (Brinkmann Instruments, Westbury, NY). The total protein concentration was determined by bicinchoninic acid assay (Thermo Fisher Scientific, Waltham, MA) and used bovine serum albumin (BSA) as standard. The total cellular protein (30 µg aliquots) was separated using Biorad 4-15 % MP TGX Stain-Free gels under SDS denaturing conditions (Biorad,

Hercules, CA) and electrotransfered onto Biorad LF PVDF membranes (Biorad, Hercules, CA) using Biorad rapid transfer kits. Blocking was carried out using Biorad EveryBlot blocking buffer with 0.01 % Tween-20 (Biorad, Hercules, CA). The membranes were probed with the following primary antibodies: rabbit anti-MMP9 (1:1000 µl , cat#AB13458, MilliporeSigma, Burlington, MA), rabbit anti-PSD-95 (1:500 µl , cat#20665-1-AP, Protein Tech, Rosemont, IL), rabbit anti-SYN1 (1:500 µl, cat#20258-1-AP, Protein Tech, Rosemont, IL), rabbit anti-MEF2C (1:500 µl , cat#10056-1-AP, Abnova, Taipei City, Taiwan), DGCR6 (1:500 µl , cat#H00008214-B01P, Protein Tech, Rosemont, IL) using VCP for the loading control (mouse anti-VCP, Santa Cruz Biotechnology cat# sc-57492 and rabbit anti-VCP, Abcam Inc. cat# ab111740). All proteins were visualized with Biorad anti-mouse Starbright blue 520 and anti-rabbit Starbright blue 700 fluorescence secondary antibodies (Biorad, Hercules, CA). Blots were imaged on a Biorad ChemicDoc MP Imaging system and analyzed using Biorad Image Lab v 6.0.1 (Biorad, Hercules, CA).

Immunohistochemistry: Triple immunofluorescence labeling was performed using monoclonal primary antibodies for the target proteins rabbit anti-MMP9 (1:500 µl , cat#AB13458, MilliporeSigma, Burlington, MA), rabbit anti-BCAN (1:500 µl , cat#19017-1-AP, Protein Tech, Rosemont, IL) biotinylated Wisteria floribunda agglutinin lectin (1:1000 µl , cat# B-1355, Vector Labs, Burlingame, CA), mouse anti-IBA1 (1:1000 µl , Wako Chemicals, cat# 013-27593) , rabbit anti-IBA1 (1:1000 µl , Wako Chemicals cat#019-19741), or mouse anti-TPSAB1 (1:500 µl , cat#66174-1-Ig, Protein Tech, Rosemont, IL) . Sections were post-fixed in 4% PFA for 30 minutes, and then co-incubated in primary antibodies in 2% bovine serum albumin (BSA) for 72 hr at 4 °C. This step was followed by 4 hour incubation at room temperature in Alexa Fluor goat anti-mouse 647 (1:300 µl; A-21235, Invitrogen, Grand Island, NY) and donkey anti-rabbit 555 (1:300 µl; A-32794, Invitrogen, Grand Island, NY), followed by 2 minutes in using TrueBlack solution for autofluorescence quenching (Biotum, cat#23007) [54, 55]. Sections were mounted and coverslipped using Dako mounting media (S3023, Dako, North America, Carpinteria, CA). All sections were coverslipped and coded for quantitative analysis blinded to diagnosis. Sections from all brains included in the study were

processed simultaneously to avoid procedural differences. Omission of streptavidin or omission of the primary or secondary antibodies were used as negative controls.

Microscopy Quantification: Sections containing the hippocampus were quantified using an Olympus BX 61 fluorescent microscope interfaced with StereoInvestigator v11 (MBF Biosciences, Williston, VT). Borders of each subregion were defined according to the Allen Brain Atlas and traced under 4x magnification. Each traced region was systematically scanned through the full x, y, and z-axes under 40x magnification to count each immunolabeled cell.

Sholl Analysis: Fluorescent multichannel images were systematically sampled from CA4 of glial fibrillary acidic protein (GFAP) labeled glial cells with or without BCAN expression and captured using a 60x oil objective (369 glial cells from subjects with ASD and 419 glial cells from control subjects obtained from 6 ASD subjects and 6 control subjects) using StereoInvestigator v 11.0 (MBF Biosciences, Williston, VT). Images were analyzed using the Sholl analysis probe in Neurolucida 360 (MBF Biosciences, Williston, VT).

Numerical Densities of Immunoreactive Cells: Numerical densities were calculated as $Nd= \sum N / \sum V$ where N = sum of all cells counted in each region, and V is the volume of each region, calculated as $V= \sum a \cdot z$, where z is the thickness of each section (30 μm) and a is area in μm2.

Statistical Analysis: Stepwise linear regression analysis of covariance was applied to the main outcome qRT-PCR, Western blotting, and microscopy measures to test differences between ASD and control groups and effects of confounding variables including age, PMI, RIN, race, history of epilepsy, and cause of death. Potential effects of these confounding covariates were tested on our outcome measures in stepwise linear regression analysis, as conducted previously [56] using JMP Pro v15.1.0 software (Cary, North Carolina).

Significance of comparisons by ANOVA is denoted by p<0.05. No information was available on severity of ASD, any comorbidities or the effects of any therapeutic drugs in the ASD group.

Results

RNAseq Profiling

RNAseq gene expression profiling identified 2851 differentially expressed genes in the hippocampus of children with ASD, including genes implicated in genetic analysis studies [56-59] and genes involved in synaptic regulation, blood vessel and blood-brain barrier regulation, immune signaling, ECM organization, and calcium channel activity (Fig. 1, Supplementary Fig.1, and Supplementary Table 1).

Gene expression pathway analysis identified upregulation of pathways involved in immune system and inflammatory response (ex: R-HSA-877300; GO0006959), vasculature regulation (ex: hsa04610) and ECM organization (ex: R-HSA-1474244) (Fig. 1, Supplementary Fig.1, and Supplementary Table 1). Furthermore, we identified downregulation of several pathways involved in synaptic signaling and synaptic transmission (ex: GO0099504; R-HSA-112314) (Fig. 1, Supplementary Figs.1&2, and Supplementary Table 1). Hierarchical cluster analysis revealed variability in both groups (Fig. 2 A). Hierarchical cluster analysis revealed expression variability among subjects and DEGs (Fig. 2 A). However, there was noticeable separation between control and ASD subjects among ECM molecules, ECM proteases, and synaptic signaling molecule genes, but weaker clustering among genes related to the immune system (Fig. 2 B-E).

qRT-PCR Confirmation of DEGs

qRT-PCR on a subset of differentially expressed genes (DEGs) from our RNAseq analysis confirmed several of the top DEGs. In particular, genes highly expressed in the hippocampus of children with ASD included IL1RL1, MMP9, OTX2 and SERPIND1 (Fig. 3A). Significantly increased expression was also detected for several additional ECM molecules including ADAMTSL4, CHST3, MMP14 and VCAN, and

decreased expression for ADAM23, ADAMTS3, SEMA3E, and SPOCK1 (Fig. 3B). Decreased gene expression was observed for CACNA1I, whereas expression for additional calcium channels and IL1beta approached significance (Fig. 3C). Decreased expression was confirmed for the genetically associated markers SYN1 and ADCYAP1 (Fig. 3D), whereas DGRC6 and RSPO1 did not approach significance between groups. Decreased expression was confirmed for the majority of the synaptic markers examined (Fig. 3E).

Western Blotting Protein Confirmation of DEGs

Western blotting analysis on several of the top candidates confirmed gene expression measures with changes in protein levels. The active and cleaved forms of MMP9 were increased in children with ASD whereas the precursor form was not significantly different between the two groups (Fig. 4 A-C). The 17 and 30 kDa isoforms of IL1beta protein were both significantly greater in children with ASD compared to age matched control subjects (Fig. 4 D&E). Furthermore, decreases in the synaptic proteins PSD95 and SYN1 were observed in subjects with ASD (Fig. 4 F-H). A significant decrease in protein expression was observed for MEF2C (Fig. 4I) but not for DGRC6 (Fig 4J).

MMP9 Expression in Microglia, Neurons and Mast Cells

MMP9 labeling in the hippocampus was observed primarily in microglia a well as a small percentage of neurons and cells displaying mast cell morphology. Tryptase alpha/beta1 (TPSAB1) labeling was used to confirm the presence of mast cells in the human hippocampus of subjects with ASD and control subjects (Supplementary Fig. 3 A-C). Immunofluorescence confirmed that MMP9 expression colocalized with mast cells (Supplementary Fig. 3 D) and microglial cells labeled with IBA1 (Supplementary Fig. 3E). Densities of MMP9 labeled mast cells were not altered in the DG or CA4 of subjects with ASD compared to control subjects (Supplementary Fig. 3 F-H).

Increased BCAN Expression in GFAP+ Astrocytes in Children With ASD

Brevican (BCAN) expression was observed in cells with astrocytic morphology, and 20- 30% of these GFAP cells displayed co-expression of BCAN (Supplementary Fig. 4 A&B). Quantification of BCAN+ and GFAP+ cells in the CA4 area of the hippocampus revealed increase density of GFAP cells co-expressing BCAN (Supplementary Fig. 4C). Densities of cells expressing BCAN only or GFAP only were not altered between groups, suggesting that a greater percentage of GFAP cells express BCAN in children with ASD. Statistical comparison of the percentages of GFAP cells expressing BCAN between groups provides additional support for increased expression of BCAN in GFAP cells in children with ASD (Supplementary Fig. 4F).

Altered Astrocyte Morphology in the Hippocampus of Children with ASD

Sholl analysis was performed on images systematically sampled from CA4 of GFAP labeled glial cells with or without BCAN expression (369 glial cells from subjects with ASD and 419 glial cells from control subjects obtained from 6 subjects per group) in order to test the hypothesis that astrocytes expressing BCAN display morphological features characteristic of immature glial cells. Glial cells were traced using the Sholl analysis probe in Neurolucida 360 (Supplementary Fig. 5 A&B) and branches were quantified for measures of branch intersections, length, surface area, volume, diameter, nodes and endings (Supplementary Fig. 5C). In control subjects, GFAP astrocytes co-expressing BCAN had significantly fewer branch intersections along with decreased branch length, surface area, volume and diameter (Supplementary Fig. 5 D-J). In comparison, GFAP astrocytes co-expressing BCAN from subjects with ASD had fewer branch intersections, nodes, and endings, along with decreased branch length (Supplementary Fig. 5 K-P). Direct comparison between ASD and control subjects revealed increased branch nodes and endings in GFAP only astrocytes in children with ASD compared to decreased branch nodes and endings in GFAP astrocytes co-expressing BCAN (Fig.4). A significant interaction between age and diagnosis was observed for branch intersections across all astrocytes examined, resulting in an opposite correlation of age with branch intersections in children with ASD compared to non-ASD control subjects (Fig. 4Q).

Rexrode et al.

Discussion:

Our results represent, to our knowledge, the first evidence for molecular abnormalities in the hippocampus of children with ASD. We detected gene expression differences between ASD and control subjects and many changes were linked to ECM regulation, inflammatory and immune signaling, and decreased synaptic signaling are in line with growing evidence for immune system [13-18] and synaptic pathology in ASD [12, 19, 57, 60, 61]. Our results highlight the potential involvement of ECM molecules with these pathways during a window of neurodevelopment in the hippocampus of children with ASD. Cluster analysis displayed the expected variability in subjects with ASD but suggests that ECM molecules and synaptic signaling molecules encompass a larger group of subjects than immune system molecules. Furthermore, our data suggest that altered expression of the ECM molecule BCAN may be associated with glial cell maturation deficits in ASD. Several genes implicated by genetic studies on ASD, including MEF2C and SYN1 [56, 57, 61, 62], displayed altered expression in our study, suggesting that these genetic factors may in part contribute to molecular pathology in the hippocampus of children with ASD.

Extracellular Matrix Molecules

Gene pathways involved in ECM organization were upregulated in the hippocampus of children with ASD (Fig. 1; Reactome pathway), together with mRNA and protein expression changes confirmed with qRT-PCR and Western Blotting for several ECM molecules (Figs. 3&4). CSPGs and their endogenous proteases are critically involved in mediating neurodevelopment, synaptic regulation, and inflammation, and thus represent key factors at the intersection of these processes in ASD.

Several of the ECM molecules upregulated in children with ASD may contribute to neuroinflammatory processes. Chondroitin sulphate (CS) is a potent inhibitor of inflammation [23, 24, 41, 42] and also inhibits human mast cells [63], activation of which has been implicated in ASD [64]. CS protects from inflammatory neurodegeneration and promotes CNS repair [42, 65]. Genetic reduction of chondroitin sulphate synthase 1 (CHSY1) causes neuroinflammation and neurodegeneration in the mouse hippocampus [41]. Increased

expression of ECM proteases may also contribute to neuroinflammation and blood-brain barrier permeability. The endogenous CSPG proteases matrix metalloproteinases (MMPs) are critically involved in promoting inflammation [66, 67]. Increased levels of the CSPG protease matrix metalloproteinase 9 (MMP9) have been reported in amniotic fluid samples of children with ASD [39]. MMPs, including MMP9, are primarily produced by astrocytes and microglia in the brain [68, 69]. MMP9 is also produced by mast cells [70, 71], and our data shows MMP9 expression predominantly in microglia and to a lesser extent in neurons and mast cells in the hippocampus of children with ASD (Supplementary Fig. 2).

Evidence from animal models supports the hypothesis that increased MMP9 expression during development contributes to decreased perineuronal nets (PNNs) and synaptic destabilization [72-74]. PNNs are ECM structures that develop around fast-firing neurons and stabilize synaptic plasticity [72-75]. Fragile-X syndrome is a monogenetic disease in which approximately 30% of patients display symptoms of ASD. Several animal models of Fragile-X syndrome show increased MMP9 expression and reductions of PNNs in the amygdala, auditory cortex and hippocampus, together with impaired fear memory [72-75]. Pharmacological inhibition of MMP9 during development or genetic reduction of MMP9 in these mice restores PNN levels and reduces anxiety [72, 73], supporting the hypothesis that elevated MMP9 during development reduces CSPGs, impairs PNN development and in turn destabilizes synapses during this developmental window.

Altered expression of ECM molecules may also contribute to neurodevelopmental dysfunction in ASD. For example, VCAN, which encodes the core CSPG protein versican, is involved in promoting synaptic maturation during development [76], as well as promoting neuronal differentiation and neurite outgrowth [77]. CHST3, which was also upregulated in ASD, encodes the enzyme involved in chondroitin 6 sulphation and is involved in promoting hippocampal synaptic plasticity and memory [78]. Our observed decreased expression of the chondroitin-heparan sulphate proteoglycan SPOCK1 in the hippocampus of children with ASD may be involved in neurodevelopmental dysfunction. SPOCK is highly expressed during brain

development in areas of neuronal migration and axonal outgrowth, as well as in synaptic fields [79]. We previously observed decreased SPOCK1 and SPOCK3 mRNA expression in the brain of subjects with schizophrenia [80], which shares genetic overlap with ASD [81]. Furthermore, decreased SPOCK expression was correlated with decreased cognitive function in subjects with schizophrenia [80], suggesting that decreased SPOCK expression may be associated with cognitive function in ASD.

Increased expression of CSPGs may be a compensatory effect to increases in ECM proteases. Increased expression of CSPGs may also reflect their roles in neurodevelopmental processes such as cell maturation, as suggested by our data on BCAN expression in astrocytes. For example, BCAN is expressed in rat hippocampal astrocytes as they mature [82], suggesting BCAN expression promotes astrocyte development. Our observed increase of BCAN positive astrocytes in children with ASD together with impaired astrocyte morphology suggests that increased expression of CSPGs may be associated with immature glial cells in the hippocampus of children with ASD (Fig. 5, Supplementary Figs. 4&5).

Synaptic Signaling

Our observed decreased gene expression in several pathways involved in synaptic regulation (Fig.1 and Supplementary Figures 1&2), as well as decreased mRNA and protein expression of synaptic markers together indicate decreased synaptic signaling in the developing hippocampus of children with ASD. We observed decreased protein expression of the synaptic marker PSD-95 (Fig. 4), which has been associated with NMDA receptor alterations and spine changes in ASD [60]. Alterations in synaptic proteins suggest that synaptic alterations in the developing brain of children with ASD may arise from genetic factors such as reported genetic mutations for SYN1 associated with ASD [57]. Evidence that loss of function genetic mutations in SYN1 have been associated with ASD and epilepsy [57], and SYN1 knockout mice display impaired social behaviors and repetitive behaviors, [61] supports this possibility. In addition, the observed increase of MMP9 expression and decreased expression of the synaptic markers PSD95 and SYN1 in the

same cohort (Fig. 4), suggests that increased MMP9 in the developing brain of children with ASD may contribute to reductions of CSPGs that are involved in stabilizing synapses.

Molecules Implicated as Genetic Factors in ASD

Several molecules that have been implicated as genetic factors for ASD, including MEF2C, SYN1, DGCR6, displayed significantly altered gene expression in our RNAseq analysis. MEF2C and SYN1 decreased expression was also confirmed with qRT-PCR and Western blotting. MEF2C haploinsufficiency has been associated with ASD as well as epilepsy and intellectual disability [56, 62, 83, 84]. Furthermore, mouse models of MEF2C haploinsufficiency demonstrate that impaired MEF2C function results in social deficits, reduced ultrasonic vocalization, hyperactivity, repetitive behavior, and synaptic regulation through both neuronal and microglial cells [56, 85]. Our findings for decreased gene and protein expression of MEF2C in the hippocampus of children with ASD provide the first evidence for altered MEF2C expression in this region in ASD and support the involvement of MEF2C in this disorder. These results also suggest that MEF2C haploinsufficiency may contribute in part to several of the altered molecular pathways observed in our study. Genetic mutations in SYN1 resulting in loss of function have also been associated with ASD and epilepsy [57]. Our observed decrease in SYN1 mRNA and protein expression suggests that SYN1 mutations may in part contribute to decreased SYN1 expression in the hippocampus of children with ASD.

DGCR6 has also been implicated as a genetic factor in ASD as part of the 22.q.11.22 deletion syndrome [58] and was one of the top DEGs in our RNAseq analysis (Supplementary Table 1). However, qRT-PCR and Western blotting measures did not detect changes in DGCR6 protein expression in the hippocampus of children with ASD (Figs 3&4). This may be due in part to the fact that RNAseq evaluates data across the entire transcript/gene and qRT-PCR only evaluates a single region of the gene that may not take into account possible splice variants. Genome-wide association studies (GWAS) implicate several ECM genes in ASD, including genes encoding for endogenous proteases such as ADAMTS3, ADAMTS5, ADAMTS14 [35-38],

suggesting that genetic factors in ECM molecules may contribute to the broad ECM gene expression changes we observed in children with ASD.

Inflammation and Immune Signaling

Several lines of evidence suggest a critical role for neuroinflammation during development in ASD, potentially contributing to synaptic abnormalities [12, 13, 15, 16, 18, 57]. Increased cytokine levels during early developmental stages are associated with increased risk of developing ASD [86-88]. Rodent models of ASD suggest that maternal immune activation and early postnatal neuroinflammation contribute to synaptic dysfunction in several brain regions [17, 89], including the hippocampus [90, 91]. Our findings for increased gene expression in inflammatory signaling pathways provide support for the involvement of neuroinflammation in the developing hippocampus of children with ASD. Several genes with significantly increased expression in our study have recently been implicated in astrocyte response to inflammation, including CXCL10, GBP2, TIMP1, SPERPINA3 [92]. A recent single cell RNAseq profiling study in postmortem samples of subjects with ASD identified altered expression of molecules involved CSPG processing in ASD, including increased expression of the CSPG sulfotransferase CSGALNACT1 in microglia, and increased expression of the endogenous CSPG proteases MMP16 and ADAMTS9 [19].

Blood-Brain Barrier Regulation

Gene pathways involved in regulation of blood vessels were upregulated in children with ASD in our study (Fig. 1: angiogenesis GO pathway; Supplemental Fig. 1 and Supplemental Table 1). Furthermore, ECM molecules are also highly involved in blood-brain barrier (BBB) regulation [93]. Our findings suggesting altered BBB composition in the hippocampus of children with ASD are in line with recent evidence for BBB dysfunction in ASD [94, 95]. Altered expression of genes involved in BBB integrity were reported in postmortem cortex and cerebellum samples from subjects with ASD, together with increased expression of MMP9 and inflammatory molecules [95]. Mutations in CHD7 have been associated with ASD and may contribute to changes in BBB glial cells that impact serotonin signaling and sleep defects [94]. CHD7 gene

expression was significantly upregulated in our RNAseq dataset (Supplementary Table 1). SERPIND1, upregulated in our dataset in children with ASD, is involved in promoting vascular endothelial function and angiogenesis [96], and is activated by glycosaminoglycans [97]. Furthermore, a recent report demonstrated that decreased SPOCK1 expression results in increased BBB leakage in the developing mouse brain [98]. We observed decreased SPOCK1 mRNA in hippocampal samples from children with ASD (Figs.1&3), suggesting that impaired SPOCK expression may contribute to BBB dysfunction in this disorder. Speculatively, our observed changes in ECM signaling pathways may contribute to altered BBB permeability and in turn increased neuroinflammation in the hippocampus of children with ASD.

In summary, our results provide evidence regarding molecular alterations in the hippocampus of children with ASD during a key neurodevelopmental period. These findings point to ECM abnormalities at the intersection of gene expression pathways involved in synaptic regulation, blood-brain barrier regulation, and neuroinflammation. Several factors implicated in genetic studies of ASD including MEF2C and SYN1 displayed altered gene expression in our study and suggest that alterations in signaling pathways involved in ECM, inflammatory signaling and synaptic regulation may be downstream from multiple genetic factors in ASD.

References:

1.   Solmi M, Song M, Yon DK, Lee SW, Fombonne E, Kim MS *et al.* Incidence, prevalence, and global burden of autism spectrum disorder from 1990 to 2019 across 204 countries. *Mol Psychiatry* 2022.

2.   Powell PS, Pazol K, Wiggins LD, Daniels JL, Dichter GS, Bradley CB *et al.* Health Status and Health Care Use Among Adolescents Identified With and Without Autism in Early Childhood - Four U.S. Sites, 2018-2020. *MMWR Morb Mortal Wkly Rep* 2021; **70**(17)**:** 605-611.

3.   Lai MC, Lombardo MV, Baron-Cohen S. Autism. *Lancet* 2014; **383**(9920)**:** 896-910.

4.   Prevention CfDCa. CDC estimates 1 in 59 children has been identified with autism spectrum disorder;. https://www.cdc.gov/features/new-autism-data/index.html,, 2018.

5.   Boucher J, Mayes A, Bigham S. Memory in autistic spectrum disorder. *Psychological bulletin* 2012; **138**(3)**:** 458-496.

6.   Barnea-Goraly N, Frazier TW, Piacenza L, Minshew NJ, Keshavan MS, Reiss AL *et al.* A preliminary longitudinal volumetric MRI study of amygdala and hippocampal volumes in autism. *Prog Neuropsychopharmacol Biol Psychiatry* 2014; **48:** 124-128.

7.   Raymond GV, Bauman ML, Kemper TL. Hippocampus in autism: a Golgi analysis. *Acta Neuropathol* 1996; **91**(1)**:** 117-119.

8.   Schumann CM, Hamstra J, Goodlin-Jones BL, Lotspeich LJ, Kwon H, Buonocore MH *et al.* The amygdala is enlarged in children but not adolescents with autism; the hippocampus is enlarged at all ages. *J Neurosci* 2004; **24**(28)**:** 6392-6401.

9.   Hitti FL, Siegelbaum SA. The hippocampal CA2 region is essential for social memory. *Nature* 2014; **508**(7494)**:** 88-92.

10.   Piskorowski RA, Nasrallah K, Diamantopoulou A, Mukai J, Hassan SI, Siegelbaum SA *et al.* Age-Dependent Specific Changes in Area CA2 of the Hippocampus and Social Memory Deficit in a Mouse Model of the 22q11.2 Deletion Syndrome. *Neuron* 2016; **89**(1)**:** 163-176.

11.   Avino TA, Barger N, Vargas MV, Carlson EL, Amaral DG, Bauman MD *et al.* Neuron numbers increase in the human amygdala from birth to adulthood, but not in autism. *Proc Natl Acad Sci U S A* 2018; **115**(14)**:** 3710-3715.

12.   Weir RK, Bauman MD, Jacobs B, Schumann CM. Protracted dendritic growth in the typically developing human amygdala and increased spine density in young ASD brains. *J Comp Neurol* 2018; **526**(2)**:** 262-274.

13.   Bauman MD, Iosif AM, Ashwood P, Braunschweig D, Lee A, Schumann CM *et al.* Maternal antibodies from mothers of children with autism alter brain growth and social behavior development in the rhesus monkey. *Transl Psychiatry* 2013; **3:** e278.

14.   Suzuki K, Sugihara G, Ouchi Y, Nakamura K, Futatsubashi M, Takebayashi K *et al.* Microglial activation in young adults with autism spectrum disorder. *JAMA Psychiatry* 2013; **70**(1)**:** 49-58.

15.   Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. *Ann Neurol* 2005; **57**(1)**:** 67-81.

16.   Hanamsagar R, Alter MD, Block CS, Sullivan H, Bolton JL, Bilbo SD. Generation of a microglial developmental index in mice and in humans reveals a sex difference in maturation and immune reactivity. *Glia* 2018; **66**(2)**:** 460.

17.   Carlezon WA, Jr., Kim W, Missig G, Finger BC, Landino SM, Alexander AJ *et al.* Maternal and early postnatal immune activation produce sex-specific effects on autism-like behaviors and neuroimmune function in mice. *Scientific reports* 2019; **9**(1)**:** 16928.

18.   Tsilioni I, Patel AB, Pantazopoulos H, Berretta S, Conti P, Leeman SE *et al.* IL-37 is increased in brains of children with autism spectrum disorder and inhibits human microglia stimulated by neurotensin. *Proc Natl Acad Sci U S A* 2019; **116**(43)**:** 21659-21665.

19. Velmeshev D, Schirmer L, Jung D, Haeussler M, Perez Y, Mayer S *et al.* Single-cell genomics identifies cell type-specific molecular changes in autism. *Science* 2019; **364**(6441)**:** 685-689.

20. Haida O, Al Sagheer T, Balbous A, Francheteau M, Matas E, Soria F *et al.* Sex-dependent behavioral deficits and neuropathology in a maternal immune activation model of autism. *Transl Psychiatry* 2019; **9**(1)**:** 124.

21. Werling DM, Geschwind DH. Sex differences in autism spectrum disorders. *Current opinion in neurology* 2013; **26**(2)**:** 146-153.

22. Ronca F, Palmieri L, Panicucci P, Ronca G. Anti-inflammatory activity of chondroitin sulfate. *Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society* 1998; **6 Suppl A:** 14-21.

23. Pomin VH. Sulfated glycans in inflammation. *European journal of medicinal chemistry* 2015; **92:** 353-369.

24. Iovu M, Dumais G, du Souich P. Anti-inflammatory activity of chondroitin sulfate. *Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society* 2008; **16 Suppl 3:** S14-18.

25. Avino TA, Hutsler JJ. Abnormal cell patterning at the cortical gray-white matter boundary in autism spectrum disorders. *Brain Res* 2010; **1360:** 138-146.

26. Wegiel J, Kuchna I, Nowicki K, Imaki H, Wegiel J, Marchi E *et al.* The neuropathology of autism: defects of neurogenesis and neuronal migration, and dysplastic changes. *Acta Neuropathol* 2010; **119**(6)**:** 755-770.

27. Gogolla N, Caroni P, Luthi A, Herry C. Perineuronal nets protect fear memories from erasure. *Science* 2009; **325**(5945)**:** 1258-1261.

28. Maeda N. Proteoglycans and neuronal migration in the cerebral cortex during development and disease. *Frontiers in neuroscience* 2015; **9:** 98.

29. Karus M, Ulc A, Ehrlich M, Czopka T, Hennen E, Fischer J *et al.* Regulation of oligodendrocyte precursor maintenance by chondroitin sulphate glycosaminoglycans. *Glia* 2016; **64**(2)**:** 270-286.

30. Pantazopoulos H, Woo T-UW, Lim MP, Lange N, Berretta S. Extracellular Matrix-Glial Abnormalities in the Amygdala and Entorhinal Cortex of Subjects Diagnosed With Schizophrenia. *Arch Gen Psychiatry* 2010; **67**(2)**:** 155-166.

31. Enwright JF, Sanapala S, Foglio A, Berry R, Fish KN, Lewis DA. Reduced Labeling of Parvalbumin Neurons and Perineuronal Nets in the Dorsolateral Prefrontal Cortex of Subjects with Schizophrenia. *Neuropsychopharmacology* 2016; **41**(9)**:** 2206-2214.

32. Guan J, Cai JJ, Ji G, Sham PC. Commonality in dysregulated expression of gene sets in cortical brains of individuals with autism, schizophrenia, and bipolar disorder. *Transl Psychiatry* 2019; **9**(1)**:** 152.

33. Sullivan PF, Magnusson C, Reichenberg A, Boman M, Dalman C, Davidson M *et al.* Family history

of schizophrenia and bipolar disorder as risk factors for autism. *Arch Gen Psychiatry* 2012; **69**(11)**:** 1099-1103.

34.   Ma D, Salyakina D, Jaworski JM, Konidari I, Whitehead PL, Andersen AN *et al.* A genome-wide association study of autism reveals a common novel risk locus at 5p14.1. *Annals of human genetics* 2009; **73**(Pt 3)**:** 263-273.

35.   Wang K, Zhang H, Ma D, Bucan M, Glessner JT, Abrahams BS *et al.* Common genetic variants on 5p14.1 associate with autism spectrum disorders. *Nature* 2009; **459**(7246)**:** 528-533.

36.   Weiss LA, Arking DE, Gene Discovery Project of Johns H, the Autism C, Daly MJ, Chakravarti A. A genome-wide linkage and association scan reveals novel loci for autism. *Nature* 2009; **461**(7265)**:** 802-808.

37.   Hussman JP, Chung RH, Griswold AJ, Jaworski JM, Salyakina D, Ma D *et al.* A noise-reduction GWAS analysis implicates altered regulation of neurite outgrowth and guidance in autism. *Mol Autism* 2011; **2**(1)**:** 1.

38.   Anney R, Klei L, Pinto D, Regan R, Conroy J, Magalhaes TR *et al.* A genome-wide scan for common alleles affecting risk for autism. *Hum Mol Genet* 2010; **19**(20)**:** 4072-4082.

39.   Abdallah MW, Pearce BD, Larsen N, Greaves-Lord K, Norgaard-Pedersen B, Hougaard DM *et al.* Amniotic fluid MMP-9 and neurotrophins in autism spectrum disorders: an exploratory study. *Autism Res* 2012; **5**(6)**:** 428-433.

40.   Slaker ML, Jorgensen ET, Hegarty DM, Liu X, Kong Y, Zhang F *et al.* Cocaine Exposure Modulates Perineuronal Nets and Synaptic Excitability of Fast-Spiking Interneurons in the Medial Prefrontal Cortex. *eNeuro* 2018; **5**(5).

41.   Macke EL, Henningsen E, Jessen E, Zumwalde NA, Landowski M, Western DE *et al.* Loss of Chondroitin Sulfate Modification Causes Inflammation and Neurodegeneration in skt Mice. *Genetics* 2020; **214**(1)**:** 121-134.

42.   Rolls A, Cahalon L, Bakalash S, Avidan H, Lider O, Schwartz M. A sulfated disaccharide derived from chondroitin sulfate proteoglycan protects against inflammation-associated neurodegeneration. *Faseb J* 2006; **20**(3)**:** 547-549.

43.   Blacktop JM, Sorg BA. Perineuronal nets in the lateral hypothalamus area regulate cue-induced reinstatement of cocaine-seeking behavior. *Neuropsychopharmacology* 2018.

44.   Morawski M, Bruckner G, Jager C, Seeger G, Arendt T. Neurons associated with aggrecan-based perineuronal nets are protected against tau pathology in subcortical regions in Alzheimer's disease. *Neuroscience* 2010; **169**(3)**:** 1347-1363.

45.   Baig S, Wilcock GK, Love S. Loss of perineuronal net N-acetylgalactosamine in Alzheimer's disease. *Acta Neuropathol* 2005; **110**(4)**:** 393-401.

46.   Jung M, Ma Y, Iyer RP, DeLeon-Pennell KY, Yabluchanskiy A, Garrett MR *et al.* IL-10 improves

cardiac remodeling after myocardial infarction by stimulating M2 macrophage polarization and fibroblast activation. *Basic research in cardiology* 2017; **112**(3)**:** 33.

47.   Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 2013; **29**(1)**:** 15-21.

48.   Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. *Nat Methods* 2017; **14**(4)**:** 417-419.

49.   Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome biology* 2014; **15**(12)**:** 550.

50.   Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z *et al.* clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. *Innovation (Camb)* 2021; **2**(3)**:** 100141.

51.   Yu G, He QY. ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization. *Molecular bioSystems* 2016; **12**(2)**:** 477-479.

52.   Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. *Nature protocols* 2008; **3**(6)**:** 1101-1108.

53.   Clark SM, Pocivavsek A, Nicholson JD, Notarangelo FM, Langenberg P, McMahon RP *et al.* Reduced kynurenine pathway metabolism and cytokine expression in the prefrontal cortex of depressed individuals. *J Psychiatry Neurosci* 2016; **41**(6)**:** 386-394.

54.   Jolly S, Lang V, Koelzer VH, Sala Frigerio C, Magno L, Salinas PC *et al.* Single-Cell Quantification of mRNA Expression in The Human Brain. *Scientific reports* 2019; **9**(1)**:** 12353.

55.   Rocco BR, Oh H, Shukla R, Mechawar N, Sibille E. Fluorescence-based cell-specific detection for laser-capture microdissection in human brain. *Scientific reports* 2017; **7**(1)**:** 14213.

56.   Harrington AJ, Bridges CM, Berto S, Blankenship K, Cho JY, Assali A *et al.* MEF2C Hypofunction in Neuronal and Neuroimmune Populations Produces MEF2C Haploinsufficiency Syndrome-like Behaviors in Mice. *Biol Psychiatry* 2020; **88**(6)**:** 488-499.

57.   Fassio A, Patry L, Congia S, Onofri F, Piton A, Gauthier J *et al.* SYN1 loss-of-function mutations in autism and partial epilepsy cause impaired synaptic function. *Hum Mol Genet* 2011; **20**(12)**:** 2297-2307.

58.   Oikonomakis V, Kosma K, Mitrakos A, Sofocleous C, Pervanidou P, Syrmou A *et al.* Recurrent copy number variations as risk factors for autism spectrum disorders: analysis of the clinical implications. *Clinical genetics* 2016; **89**(6)**:** 708-718.

59.   Brandau DT, Lund M, Cooley LD, Sanger WG, Butler MG. Autistic and dysmorphic features associated with a submicroscopic 2q33.3-q34 interstitial deletion detected by array comparative genomic hybridization. *American journal of medical genetics Part A* 2008; **146A**(4)**:** 521-524.

60.   Coley AA, Gao WJ. PSD95: A synaptic protein implicated in schizophrenia or autism? *Prog*

Neuropsychopharmacol Biol Psychiatry 2018; **82:** 187-194.

61. Greco B, Manago F, Tucci V, Kao HT, Valtorta F, Benfenati F. Autism-related behavioral abnormalities in synapsin knockout mice. *Behav Brain Res* 2013; **251:** 65-74.

62. Paciorkowski AR, Traylor RN, Rosenfeld JA, Hoover JM, Harris CJ, Winter S *et al.* MEF2C Haploinsufficiency features consistent hyperkinesis, variable epilepsy, and has a role in dorsal and ventral neuronal developmental pathways. *Neurogenetics* 2013; **14**(2)**:** 99-111.

63. Gross AR, Theoharides TC. Chondroitin sulfate inhibits secretion of TNF and CXCL8 from human mast cells stimulated by IL-33. *Biofactors* 2019; **45**(1)**:** 49-61.

64. Theoharides TC, Kavalioti M, Tsilioni I. Mast Cells, Stress, Fear and Autism Spectrum Disorder. *International journal of molecular sciences* 2019; **20**(15).

65. Rolls A, Avidan H, Cahalon L, Schori H, Bakalash S, Litvak V *et al.* A disaccharide derived from chondroitin sulphate proteoglycan promotes central nervous system repair in rats and mice. *Eur J Neurosci* 2004; **20**(8)**:** 1973-1983.

66. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. *Nat Rev Immunol* 2004; **4**(8)**:** 617-629.

67. Muri L, Leppert D, Grandgirard D, Leib SL. MMPs and ADAMs in neurological infectious diseases and multiple sclerosis. *Cell Mol Life Sci* 2019; **76**(16)**:** 3097-3116.

68. Rosenberg GA, Cunningham LA, Wallace J, Alexander S, Estrada EY, Grossetete M *et al.* Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. *Brain Res* 2001; **893**(1-2)**:** 104-112.

69. Cahoy JD, Emery B, Kaushal A, Foo LC, Zamanian JL, Christopherson KS *et al.* A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. *J Neurosci* 2008; **28**(1)**:** 264-278.

70. Baram D, Vaday GG, Salamon P, Drucker I, Hershkoviz R, Mekori YA. Human mast cells release metalloproteinase-9 on contact with activated T cells: juxtacrine regulation by TNF-alpha. *J Immunol* 2001; **167**(7)**:** 4008-4016.

71. Kanbe N, Tanaka A, Kanbe M, Itakura A, Kurosawa M, Matsuda H. Human mast cells produce matrix metalloproteinase 9. *European journal of immunology* 1999; **29**(8)**:** 2645-2649.

72. Wen TH, Afroz S, Reinhard SM, Palacios AR, Tapia K, Binder DK *et al.* Genetic Reduction of Matrix Metalloproteinase-9 Promotes Formation of Perineuronal Nets Around Parvalbumin-Expressing Interneurons and Normalizes Auditory Cortex Responses in Developing Fmr1 Knock-Out Mice. *Cereb Cortex* 2018; **28**(11)**:** 3951-3964.

73. Pirbhoy PS, Rais M, Lovelace JW, Woodard W, Razak KA, Binder DK *et al.* Acute pharmacological inhibition of matrix metalloproteinase-9 activity during development restores perineuronal net

Rexrode et al.

formation and normalizes auditory processing in Fmr1 KO mice. *J Neurochem* 2020.

74.   Reinhard SM, Rais M, Afroz S, Hanania Y, Pendi K, Espinoza K *et al.* Reduced perineuronal net expression in Fmr1 KO mice auditory cortex and amygdala is linked to impaired fear-associated memory. *Neurobiol Learn Mem* 2019; **164:** 107042.

75.   Bilousova TV, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW *et al.* Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. *Journal of medical genetics* 2009; **46**(2)**:** 94-102.

76.   Yamagata M, Sanes JR. Versican in the developing brain: lamina-specific expression in interneuronal subsets and role in presynaptic maturation. *J Neurosci* 2005; **25**(37)**:** 8457-8467.

77.   Wu Y, Sheng W, Chen L, Dong H, Lee V, Lu F *et al.* Versican V1 isoform induces neuronal differentiation and promotes neurite outgrowth. *Mol Biol Cell* 2004; **15**(5)**:** 2093-2104.

78.   Yang S, Gigout S, Molinaro A, Naito-Matsui Y, Hilton S, Foscarin S *et al.* Chondroitin 6-sulphate is required for neuroplasticity and memory in ageing. *Mol Psychiatry* 2021; **26**(10)**:** 5658-5668.

79.   Charbonnier F, Chanoine C, Cifuentes-Diaz C, Gallien CL, Rieger F, Alliel PM *et al.* Expression of the proteoglycan SPOCK during mouse embryo development. *Mech Dev* 2000; **90**(2)**:** 317-321.

80.   Pantazopoulos H, Katsel P, Haroutunian V, Chelini G, Klengel T, Berretta S. Molecular signature of extracellular matrix pathology in schizophrenia. *Eur J Neurosci* 2021; **53**(12)**:** 3960-3987.

81.   Cross-Disorder Group of the Psychiatric Genomics C, Lee SH, Ripke S, Neale BM, Faraone SV, Purcell SM *et al.* Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. *Nat Genet* 2013; **45**(9)**:** 984-994.

82.   Ogawa T, Hagihara K, Suzuki M, Yamaguchi Y. Brevican in the developing hippocampal fimbria: differential expression in myelinating oligodendrocytes and adult astrocytes suggests a dual role for brevican in central nervous system fiber tract development. *J Comp Neurol* 2001; **432**(3)**:** 285-295.

83.   Lipton SA, Li H, Zaremba JD, McKercher SR, Cui J, Kang YJ *et al.* Autistic phenotype from MEF2C knockout cells. *Science* 2009; **323**(5911)**:** 208.

84.   Mikhail FM, Lose EJ, Robin NH, Descartes MD, Rutledge KD, Rutledge SL *et al.* Clinically relevant single gene or intragenic deletions encompassing critical neurodevelopmental genes in patients with developmental delay, mental retardation, and/or autism spectrum disorders. *American journal of medical genetics Part A* 2011; **155A**(10)**:** 2386-2396.

85.   Harrington AJ, Raissi A, Rajkovich K, Berto S, Kumar J, Molinaro G *et al.* MEF2C regulates cortical inhibitory and excitatory synapses and behaviors relevant to neurodevelopmental disorders. *eLife* 2016; **5**.

86.   Glasson EJ, Bower C, Petterson B, de Klerk N, Chaney G, Hallmayer JF. Perinatal factors and the development of autism: a population study. *Arch Gen Psychiatry* 2004; **61**(6)**:** 618-627.

87.   Gardener H, Spiegelman D, Buka SL. Perinatal and neonatal risk factors for autism: a comprehensive meta-analysis. *Pediatrics* 2011; **128**(2)**:** 344-355.

88.   Kolevzon A, Gross R, Reichenberg A. Prenatal and perinatal risk factors for autism: a review and integration of findings. *Archives of pediatrics & adolescent medicine* 2007; **161**(4)**:** 326-333.

89.   Li Y, Missig G, Finger BC, Landino SM, Alexander AJ, Mokler EL *et al.* Maternal and Early Postnatal Immune Activation Produce Dissociable Effects on Neurotransmission in mPFC-Amygdala Circuits. *J Neurosci* 2018; **38**(13)**:** 3358-3372.

90.   Giovanoli S, Weber-Stadlbauer U, Schedlowski M, Meyer U, Engler H. Prenatal immune activation causes hippocampal synaptic deficits in the absence of overt microglia anomalies. *Brain Behav Immun* 2016; **55:** 25-38.

91.   Oh-Nishi A, Obayashi S, Sugihara I, Minamimoto T, Suhara T. Maternal immune activation by polyriboinosinic-polyribocytidilic acid injection produces synaptic dysfunction but not neuronal loss in the hippocampus of juvenile rat offspring. *Brain Res* 2010; **1363:** 170-179.

92.   Hasel P, Rose IVL, Sadick JS, Kim RD, Liddelow SA. Neuroinflammatory astrocyte subtypes in the mouse brain. *Nat Neurosci* 2021; **24**(10)**:** 1475-1487.

93.   Tabet A, Apra C, Stranahan AM, Anikeeva P. Changes in Brain Neuroimmunology Following Injury and Disease. *Frontiers in integrative neuroscience* 2022; **16:** 894500.

94.   Coll-Tane M, Gong NN, Belfer SJ, van Renssen LV, Kurtz-Nelson EC, Szuperak M *et al.* The CHD8/CHD7/Kismet family links blood-brain barrier glia and serotonin to ASD-associated sleep defects. *Sci Adv* 2021; **7**(23).

95.   Fiorentino M, Sapone A, Senger S, Camhi SS, Kadzielski SM, Buie TM *et al.* Blood-brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders. *Mol Autism* 2016; **7:** 49.

96.   Ikeda Y, Aihara K, Yoshida S, Iwase T, Tajima S, Izawa-Ishizawa Y *et al.* Heparin cofactor II, a serine protease inhibitor, promotes angiogenesis via activation of the AMP-activated protein kinase-endothelial nitric-oxide synthase signaling pathway. *J Biol Chem* 2012; **287**(41)**:** 34256-34263.

97.   Tollefsen DM. Heparin cofactor II modulates the response to vascular injury. *Arterioscler Thromb Vasc Biol* 2007; **27**(3)**:** 454-460.

98.   O'Brown NM, Patel NB, Hartmann U, Klein AM, Gu C, Megason SG. The secreted neuronal signal Spock1 regulates the blood-brain barrier. *bioRxiv* 2021**:** 2021.2010.2013.464312.

Acknowledgments: We thank the NIH NeuroBioBank (https://neurobiobank.nih.gov/) for making the human brain samples available. The authors deeply appreciate the invaluable contributions made by the families consenting to donate brain tissue. This work was funded by support from the Inflammation Healing Foundation.

Rexrode et al.

Conflict of Interest Statement: The authors have no competing financial interests to disclose.

Data Availability Statement: Gene expression profiling data will be publicly available on NCBI dbGaP upon manuscript publication. All other data are available in the main text or supplementary materials.

Figure 1: Differential Gene Expression Pathways in the Hippocampus of Children with ASD. (A) Volcano plot of DGE: ASD vs. non-ASD controls. On the x-axis is log fold change of genes in subjects with ASD compared to controls, points to the right of 0 represent genes that are increased, and points to the left of 0 genes that are decreased, in ASD compared to controls. Statistical significance is displayed on the y-axis, and p < 0.05 are labeled in blue. Select genes with both high fold change and significance are labeled. The top dozen GSEA Reactome analysis identified upregulated pathways, (including extracellular matrix organization and immune signaling pathways), and downregulated pathways involved in synaptic regulation in children with ASD (B). Similar top pathways were detected with GSEA GO BP analysis (C). Reactome tree and GO tree plots of pathways altered in children with ASD (D&E). GSEA GO enrichment plot of upregulated and downregulated pathways in children with ASD (F).

Figure 2: Hierarchical Cluster Analysis. (A) Hierarchical clustering of 7 ASD and 6 non-ASD control subjects using variance-stabilized expression of 2851 genes differentially expressed between ASD and non-ASD control subjects in the hippocampus (p-adjusted < 0.05). Hierarchical cluster analysis using differentially expressed genes for extracellular matrix molecules (B), extracellular matrix degradation molecules (C), immune signaling (D), and synaptic molecules and genetic factors (E).

Figure 3: qPCR Confirmation of Differentially Expressed Genes. qPCR analysis was conducted on a subset of 28 genes with differential expression from our RNAseq analysis as well as the downstream extracellular matrix protease MMP9 and the inflammatory signaling gene IL1B. Significantly increased expression was detected for genes highly expressed in the hippocampus of children with ASD (A). Altered expression was confirmed for several extracellular matrix molecules (B) and the L-type Ca channel

CACNA1I (C). Altered gene expression was also confirmed for several genes implicated as genetic factors for ASD (D) and for synaptic molecules (E). *adjusted for significant effects of age and PMI. Significance values are derived from stepwise linear regression models. Bar graphs depict the mean (histogram) and 95% confidence intervals (black lines).

Figure 4: Protein Analysis of MMP9, Synaptic Markers and Genetically Associated Molecules. Western blot analysis was conducted on the extracellular matrix protease MMP9 and the synaptic markers PSD95 and SYN1, as well as the genetically associated molecules MEF2C and DGCR6. (A) No difference was observed for the 92 kDa isoform of MMP9, whereas expression of the 82 kDa (B) and 65 kDa (C) isoforms were increased in children with ASD. (D) Representative Western blots of MMP9. Expression of the broad postsynaptic marker PSD95 was decreased in children with ASD (E), along with decreased expression of the 86 kDa (F) and 80 kDa (G) isoforms of the synaptic marker SYN1. Expression of MEF2C, a molecule associated with ASD in genetic studies, was significantly decreased in children with ASD (H), whereas no difference was observed for expression of genetically associated molecule DGCR6 (I). Significance values are derived from stepwise linear regression models. Bar graphs depict the mean (histogram) and 95% confidence intervals (black lines).

Figure 5: Altered Astrocyte Morphology in the Hippocampus of Children with ASD. Sholl analysis was conducted on a subset of samples from children with ASD and non-ASD control subjects (n=6/group). (A) No differences in branch intersections, branch length, surface area, or volume, were observed between diagnosis groups for astrocytes expressing GFAP only (A-D). A significant decrease was observed for branch diameter (E) together with an increase in branch nodes and endings (F&G) for GFAP only astrocytes in children with ASD. No differences were detected for branch intersections, branch length, surface area, volume, or diameter for astrocytes co-labeled with GFAP and BCAN (H-L). Branch nodes and endings were significantly decreases in GFAP-BCAN astrocytes from children with ASD (M&N). Representative tracings of a GFAP-BCAN astrocyte from a control subject (O) and a subject with ASD (P). Branch intersections across all astrocytes displayed a significant interaction between age and diagnosis, resulting in a negative correlation of intersections by age in control subjects compared to a positive correlation in subjects with ASD (Q). Blue circles represent values from subjects with ASD, white circles represent values from control subjects. Significance values are derived from stepwise linear regression models. Bar graphs depict the mean (histogram) and 95% confidence intervals (black lines).

Table 1: Subjects and demographic information

Age	Sex	Race	RIN	PMI (hrs)	Hemisphere	Epilepsy	Cause of Death	Measures (RNAseq+qPCR, Western, Microscopy)
5-10	Male	Black	7.4	18	Left	No	natural	Western
5-10	Male	Black	8.4	16	Left	No	natural	RNA, Western, Microscopy
10-15	Male	Black	6.8	16	Left	No	natural	RNA, Western, Microscopy
10-15	Male	Black	6.8	20	Left	No	undetermined	RNA, Western, Microscopy
10-15	Male	Hispanic	2.4	15	Left	No	not available	RNA, Western, Microscopy
10-15	Male	White	7.5	13	Left	No	accidental	Western
5-10	Male	White	6.9	12	Left	No	accidental	RNA, Western, Microscopy
5-10	Male	Black	7.6	16	Left	No	accidental	RNA, Western, Microscopy
mean ± SD 9.6± 3.25	8 M	5B, 2W, 1H	6.7± 1.8	15.8 ±2.5	8 Left	8 No		

Age	Sex	Race	RIN	PMI (hrs)	Hemisphere	Epilepsy	Cause of Death	Measures (RNAseq+qPCR, Western, Microscopy)
5-10	Male	N/A	7.1	12	Left	N/A	N/A	RNA, Western
5-10	Male	Hispanic	7.1	27	Left	No	natural	RNA, Western, Microscopy
5-10	Male	Black	6.7	20	Left	No	accidental	Western
5-10	Male	White	7.7	3	Left	No	natural	RNA, Western, Microscopy
5-10	Male	White	6.0	21	Left	No	accidental	RNA, Western, Microscopy
10-15	Male	N/A	4.8	20	Left	N/A	N/A	RNA, Western, Microscopy
10-15	Male	Black	8.3	22	Left	Yes	natural	RNA, Western, Microscopy
10-15	Male	N/A	6.5	15	Left	N/A	N/A	RNA, Western, Microscopy
mean ± SD 6.6± 2.83	8 M	2B, 2W, 1H, 3 N/A	6.8± 1.1	17.5 ±7.4	8 Left	4 No, 1 Yes, 3 N/A		

Rexrode et al.